MedWatch

Novo Nordisk signed deals to the tune of billions as part of major strategy shift

In 2018, Novo Nordisk entered agreements with a potential value of totaling DKK 16.3 billion (USD 2.5 billion). In addition, the danish drug group signed several deals with an undisclosed value. A necessary development in changing times, says analysts.

Foto: /Ritzau Scanpix/Linda Kastrup

Denmark's largest drug group Novo Nordisk is in a period of change unlike anything else since the 'genesis' of the company's present form at the turn of the millennium, when the pharma-, enzyme- and investment businesses were separated between Novo Nordisk, Novozymes and Novo Holdings.

"Novo Nordisk is facing more challenges than ever, and they have done that for a few years. They are much more challenged than they have been since the early 2000s, and they will continue to be so in future," says Søren Løntoft Hansen, Senior Analyst in Sydbank.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

EU-lande blåstempler nye beføjelser til agentur

Det europæiske center for sygdomsforebyggelse og -kontrol, ECDC, får nu nye muskler til kontrol og netværksopbygning i kampen mod fremtidens epidemier. ”Dagens aftale er lig med state-of-the-art overvågning,” siger EU-topfolk.

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier